Showing 1551-1560 of 7678 results for "".
The Art of Patient Scheduling
https://practicaldermatology.com/topics/practice-management/the-art-of-patient-scheduling/23676/Is your patient scheduling system working as efficiently as possible? Put these five action items in place to ensure your practice is firing on all cylinders.Scientifically Speaking: Optimizing Results with PRP
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-optimizing-results-with-prp/20034/As increasing evidence shows the benefits of PRP for hair loss, more practices are adding it to their menu. But the results of treatment can vary depending on numerous factors. Glynis Ablon, MD and Jeffrey Rapaport, MD talk to host Joel L. Cohen, MD about their approach and share expert tips to optiDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global PSkin Reactions: Understanding New Drug Adverse Effects
https://practicaldermatology.com/conferences/aad-summer-2021/skin-reactions-understanding-new-drug-adverse-effects/19975/In addition to needing to stay abreast of new drugs in dermatology, it's important for dermatologists to stay informed about new medications that come to market in general. Vinod Nambudiri, MD, MBA says there are often dermatology-related adverse events that need to be managed. He discusses new cancAll About Innovations at DERM2021
https://practicaldermatology.com/series/dermatology-education-foundation/all-about-innovations-at-derm2021/19965/Whether you’re a new or experienced learner in the dermatology PA/NP space, Sandri Johnson, FNP-BC, says the DERM2021 NP/PA CME Conference has something to offer. Attendees will learn about the latest innovations in the field.An Excellent Networking Opportunity: DERM2021
https://practicaldermatology.com/series/dermatology-education-foundation/an-excellent-networking-opportunity-derm2021/19963/From opportunities to connect and network with other NPs and PAs to going to sessions presented by some of her favorite dermatologists, such as Ted Rosen, MD, to learn about what’s in the pipeline and coming to market soon, Leigh Ann Pansch, MSN, FNP-BC, DCNP is excited to attend the DERM2021 NP/PAStrategies to Boost Top-Line Revenue in 2021 (and Beyond)
https://practicaldermatology.com/topics/practice-management/strategies-to-boost-top-line-revenue-in-2021-and-beyond/23512/Why it takes more than simple cost-cutting measures to improve profitability.DermWireTV: Derm Salaries Down, Allergan Eyes Soliton, Emsculpt Week
https://practicaldermatology.com/topics/practice-management/dermwiretv-derm-salaries-down-allergan-eyes-soliton-emsculpt-week/19941/Just under half of all physicians in the US are employed in physician-owned medical practices, new data from the American Medical Association show. Medscape’s annual Physician Compensation Report reveals that physicians overall saw a reduction in income due to the COVID-19 pandemic; income for dermThe Expanding Role for PD-1 Inhibitors for NMSCs
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-expanding-role-for-pd-1-inhibitors-for-nmscs/19937/The pool of potential patients that could be treated with PD-1 inhibitors is growing. Todd Schlesinger, MD discusses how these drugs may be used to treat a greater number of patients with NMSCs and addresses side effects and their management.Opportunities and Barriers in Teledermatology
https://practicaldermatology.com/conferences/aad-2021/opportunities-and-barriers-in-teledermatology/19923/Dermatologists' participation in telemedicine has increased exponentially over the past year. But what does the future hold? What opportunities exist and what challenges remain? Jules Lipoff, MD weighs in.